NCT00083460View on ClinicalTrials.gov

Study of Combination PS-341 and Thalidomide in Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

PS-341

Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2

DRUG

Thalidomide

In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.

DRUG

Dexamethasone

A dose of 20mg for cylces 3-8.

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00083460 - Study of Combination PS-341 and Thalidomide in Multiple Myeloma | Biotech Hunter | Biotech Hunter